9 enrolling by invitation. 9 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Enrolling by invitation 9 |
| Phase 2 | 5 | Enrolling by invitation 5 |
Follow Neuroectodermal Tumors: new trials by email Literature Review of Neuroectodermal Tumors trials Research Report on Neuroectodermal Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma Nivolumab, Azacitidine (AZA), lumbar puncture - Glioblastoma (GBM), Diffuse Midline Glioma (DMG) | Phase 1 | Enrolling by invitation | Andrew P. Groves | 34 | 2025-06-05 | 2026-10-27 |
| Clinical Study of a Novel Oncolytic Virus Ad-TD-nsIL12 in the Treatment of Primary High-grade Glioma Novel oncolytic virus Ad-TD-nsIL12 - Glioma | Phase 1 / Phase 2 | Enrolling by invitation | Xiaorong Wu | 40 | 2025-02-12 | 2026-03-23 |
| Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma. BioTTT001 injection - Recurrent High-grade Glioma | Phase 1 / Phase 2 | Enrolling by invitation | Beijing Bio-Targeting Therapeutics Technology Co., Ltd | 30 | 2024-11-26 | 2026-03-23 |
| A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma AK104+Axitinib, AK112+Axitinib - Melanoma, Mucosal Melanoma | Phase 1 | Enrolling by invitation | Peking University Cancer Hospital & Institute | 60 | 2024-05-28 | 2026-07-13 |
| Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors PET/CT ([18F]AlF-NOTA-PCP2), [18F]AlF-NOTA-PCP2 PET/CT Imaging for PD-L1 Expression in Malignant Tumors - Glioblastoma (GBM), Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Enrolling by invitation | Man Hu | 100 | 2024-03-30 | 2025-03-30 |
| The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM SNC109 - Recurrent Glioblastoma Multiforme (GBM) | Phase 1 | Enrolling by invitation | Shanghai Simnova Biotechnology Co.,Ltd. | 50 | 2023-12-26 | 2024-09-27 |
| GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma GPC2 CAR T cells - Refractory Neuroblastoma, Relapsed Neuroblastoma | Phase 1 | Enrolling by invitation | Stephan Grupp MD PhD | 45 | 2023-05-23 | 2026-08-14 |
| Melphalan Chemoreduction for Ocular Melanoma Melphalan Injection, Plaque brachytherapy - Uveal Melanoma | Phase 1 / Phase 2 | Enrolling by invitation | Hospital das Clínicas de Ribeirão Preto | 10 | 2021-05-01 | 2025-09-15 |
| The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous CIK Cells cytokine induced killer cells - Cholangiocarcinoma, Neuroblastoma | Phase 1 / Phase 2 | Enrolling by invitation | Siriraj Hospital | 20 | 2009-04-17 | 2025-02-10 |
Glioblastoma (3) · Glioma (2) · Melanoma (2) · Neuroblastoma (2) · Adenoviridae Infections (1) · Astrocytoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Cholangiocarcinoma (1) · Esophageal Neoplasms (1) · Retinoblastoma (1) · Squamous Cell Carcinoma of Head and Neck (1) · Uveal Melanoma (1)
Neoplasms (9) · Neoplasms by Histologic Type (9) · Neoplasms, Germ Cell and Embryonal (9) · Neoplasms, Nerve Tissue (9) · Neoplasms, Glandular and Epithelial (7) · Neoplasms, Neuroepithelial (7) · Neoplasms by Site (4) · Glioma (3) · Astrocytoma (2) · Carcinoma (2) · Eye Diseases (2) · Eye Neoplasms (2) · Neuroectodermal Tumors, Primitive (2) · Neuroectodermal Tumors, Primitive, Peripheral (2)
Azacitidine (1) · Brachytherapy (1) · Melphalan (1) · Nivolumab (1) · Radiotherapy (1) · Ruthenium-106 (1) · Spinal Puncture (1)
Andrew P. Groves (1) · Beijing Bio-Targeting Therapeutics Technology Co., Ltd (1) · Hospital das Clínicas de Ribeirão Preto (1) · Man Hu (1) · Peking University Cancer Hospital & Institute (1) · Shanghai Simnova Biotechnology Co.,Ltd. (1) · Siriraj Hospital (1) · Stephan Grupp MD PhD (1) · Xiaorong Wu (1)
China (5) · United States (2) · Brazil (1) · Thailand (1)
Adisak Wongkajornsilp, M.D., Ph.D. (1) · Jun Guo, MD (1) · Lisa Wray, MD (1) · Man Hu, Dr. (1) · Rodrigo Jorge, MD, PhD (1)
PMID 38291578, PMID 38713298, PMID 41026583
R37CA282041 (1)